Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Scalp tourniquets did not significantly prevent hair loss from chemotherapy.

Platelet-rich plasma doesn't prevent hair loss from chemotherapy, and mononuclear cells only help against hair loss from one specific chemotherapy drug.

This article is a letter to the editors about a novel observation regarding chemotherapy-induced alopecia and does not include an abstract with new research results.

In this study, N. sativa oil and decoction significantly protected against chemotherapy-induced alopecia in albino rats.

This article provides guidance on managing systemic lupus erythematosus without presenting new research findings, emphasizing the role of clinical nurse specialists and the importance of lifestyle modifications and appropriate medication regimens.

This study found that scalp cooling did not entirely prevent permanent chemotherapy-induced alopecia in breast cancer patients, with a significant risk observed among postmenopausal women undergoing anthracycline and taxane-based chemotherapy.

This case report observed a dramatic improvement in a 15-year-old girl's pachyonychia congenita symptoms during chemotherapy for Ewing sarcoma, suggesting chemotherapy's potential role in managing hyperkeratotic conditions.

This case report describes a middle-aged woman whose scalp condition, cutis verticis gyrata, was an early sign of systemic amyloidosis that went undiagnosed until after she experienced a stroke.

This case report describes a 56-year-old man with late-onset systemic lupus erythematosus where digital gangrene was an initial manifestation, highlighting its rarity as a primary sign.

This case study describes a 4-year-old boy with juvenile dermatomyositis whose severe subcutaneous edema resisted conventional treatment, necessitating aggressive immunosuppression for disease control.

Chemotherapy patients don't all lose their hair due to factors like hair growth rates, age, genetics, and the type of drugs used.

This study developed a method to quantify hair loss in mice, aiding the evaluation of new treatments for alopecia.

This case report describes a patient with diffuse large B cell lymphoma who experienced temporary Beau’s lines and onycholysis while undergoing R-CHOP chemotherapy, which resolved two months after treatment ended.

This article highlights that nurses may not be sufficiently aware of the potential for various drug groups, beyond cytotoxic drugs, to cause alopecia, and emphasizes the importance of early recognition of this side effect.

This study reported that VCP combination chemotherapy achieved a complete response in 53% of advanced non-Hodgkin's lymphoma patients, although more intensive treatment may be needed for improved outcomes.

In this study, researchers observed that extract from Eclipta prostrata significantly stimulated hair growth and increased hair length in Wistar rats, which had inhibited hair growth induced by cyclophosphamide, compared to the control model.

In rats with cyclophosphamide-induced hair loss, this study found that applying cetirizine HCl-loaded emulgel with microneedling stimulated hair growth, suggesting a potentially safer alternative to minoxidil for treating chemotherapy-induced alopecia.

In this study, researchers developed and tested a novel peptide, AMHR2BP, which mimics the function of Anti-Müllerian hormone to protect ovarian follicles in mice, showing promise for preserving ovarian health during chemotherapy without causing toxicity.

This scoping review found that chemotherapy-induced alopecia in breast cancer patients, especially when using anthracycline- and taxane-based regimens, occurs at higher rates and with more persistence than historically reported.

This case report describes how anifrolumab, used beyond trial-eligible populations, led to significant clinical and serological recovery in a 45-year-old woman with organ-threatening systemic lupus erythematosus complicated by infection and resistant to conventional treatments like cyclophosphamide and rituximab.

The researchers reported that administration of the antioxidant compound TS-13 in mice with chemotherapy-induced alopecia accelerated hair regrowth, although it did not fully prevent chemotherapy-related hair loss, suggesting TS-13 may aid in managing hair loss without negating the cancer treatment's effectiveness.

In this case study, a 43-year-old male with anti-GBM disease experienced a relapse triggered by hair dye, leading to diffuse alveolar hemorrhage; managing this with plasmapheresis, intravenous immunoglobulins, and rituximab suggests rituximab may be beneficial for relapsing cases.

In this case report, a 31-year-old woman with severe multisystem lupus vasculitis initially presented with generalized pain and rapidly worsening neuropathy, ultimately improving with cyclophosphamide and prednisolone treatment. The authors highlight diagnostic challenges, particularly in interpreting autoantibody results after IVIG therapy.

In this study, the researchers using Shh-GFP^+/- mice found that cyclophosphamide-induced alopecia involves the JAK/STAT1 pathway, where STAT1 binds the Shh gene promoter, decreasing Shh-expressing cells in hair follicles. Treatment with JAK inhibitors helped rescue hair loss, implicating the JAK/STAT1 pathway in this process.

In this study, TS-13, an antioxidant, accelerated hair regrowth in a mouse model of chemotherapy-induced alopecia but did not completely prevent cyclophosphamide's hair loss effects, showing potential for mitigating such side effects without interfering with the drug's therapeutic action.

In this murine study, researchers found that topical treatment with Philippine stingless bee propolis increased folliculogenesis, epidermal thickness, and melanogenesis, but not hair length, potentially supporting hair follicle regeneration and melanocyte function in chemotherapy-induced alopecia models.

In this study, researchers observed diffuse hair loss in Japanese patients post-hematopoietic stem cell transplantation and chemotherapy, with treatments targeting hair follicle miniaturization, like topical minoxidil, improving hair volume in about 52.9% of cases.

This study found that adding cyclophosphamide to glucocorticoid treatment for pemphigus patients led to earlier remission, with 89.5% achieving remission within 4 months compared to 73.9% with glucocorticoids alone, suggesting significant steroid-sparing effects and improved clinical outcomes.

This case report from BIRDEM General Hospital describes a 17-year-old girl with systemic lupus erythematosus who developed a rare form of lupus enteritis affecting her colon and rectum. Her symptoms improved significantly after treatment with corticosteroids and immunosuppressants.

This study found that a fenugreek seed extract nanoformulation significantly improved hair growth and length in Wistar rats with alopecia, outperforming conventional gels and oils, suggesting enhanced skin penetration and reduced side effects.